# World Medicine Scales to 318th in Turkey’s Top 500 Industrial Enterprises Index

> Advancing 24 positions to rank 318th in the ISO 500 listings, World Medicine has officially validated its continuous scaling across the global healthcare market.

Published: 2026-06-22T07:56:00+00:00
Language: en
Categories: [Pharmaceutical Industry](https://chemexworld.com/en/categories/sectors/pharmaceutical-industry-1.md)

Canonical URL:
https://chemexworld.com/en/news/world-medicine-scales-to-318th-in-turkeys-top-500-industrial-enterprises-index

## Content

As international healthcare markets mandate strict regulatory alignments, advanced biochemical analyses, and capital-intensive biotech roadmaps, high-margin pharmaceutical manufacturing remains a vital driver of sovereign industrial performance.**World Medicine**, a prominent entity inside the regional pharmaceutical production landscape, continues to accelerate its trajectory across primary manufacturing indices. According to the newly declassified *"Top 500 Industrial Enterprises of Turkey"* registry monitored by the Istanbul Chamber of Industry (ISO), the corporation **climbed 24 positions to rank 318th**, validating its extensive operational scaling and specialized research infrastructure.

## Decentralizing Global Supply: Regional Manufacturing Hubs and Capital Re-Allocation

Holding its baseline position as the domestic market's top pharmaceutical exporter for five consecutive years, World Medicine commands a commercial footprint spanning **over 65 target countries**. Currently ranked among the top 20 preferred pharmaceutical suppliers across its primary operational geographies, the group is deploying specific cross-border capacity targets:

- **Manufacturing Output Matrix:** Consolidated operations across its core Istanbul and Çerkezköy production complexes have crossed an aggregate threshold of **over 1 billion packaging units per annum**.
- **Sovereign Industrial Footprints:** Shifting away from a single-hub export architecture, the enterprise is setting up localized ecosystems via its regional manufacturing plant in Algeria and its new strategic facility scheduled to online at the **Tashkent Pharma Park in Uzbekistan by the end of 2027**.
- **R&D Capital Earmarks:** To lock in next-generation clinical pipelines, World Medicine structurally re-allocates **approximately 5% of its gross corporate turnover** into specialized R&D programs, specifically backing oncology and complex biological molecules.

## WMARGE and WMINOLAB: High-Precision Regulatory Analytics

The primary catalyst driving World Medicine's high-speed market entry and swift regulatory dossier clearances is its internal laboratory architecture. Operating the advanced **WMARGE** cell and the ISO 17025-accredited **WMINOLAB Innovation Laboratory**, the enterprise executes complex, high-tier analytical testing internally, minimizing external contract research dependencies:

- **Extractables & Leachables (E&L):** Monitoring complex interaction dynamics between packaging polymers and active pharmaceutical ingredients (APIs).
- **Nitrosamine Risk Assessments:** Implementing precise screening methods to eliminate genotoxic trace impurities.
- **Franz Diffusion Cells:** Conducting in vitro release testing (IVRT) to map the kinetic performance of advanced semi-solid and topical formulations.

## Biological Re-Alignment: Structuring the Transnational Portfolio

Positioning biosimilar development at the absolute center of its upcoming five-year growth cycle, World Medicine finalized a strategic alliance with global biotechnology pioneer **Bio-Thera Solutions**. This collaboration, anchored by a comprehensive licensing agreement for **Ustekinumab**, positions the company to capture prominent market shares within high-value global therapeutic categories.